Clinical Trials Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Pulmonary Disease
Parion Sciences and Gilead Sciences Sign Agreement to Advance Drug Candidates for Pulmonary Disease
August 27th, 2007
Parion Sciences, Inc. and Gilead Sciences, Inc. (Nasdaq:GILD) announced that they have entered into an exclusive licensing and co-development agreement focused on P-680, an epithelial sodium channel (ENaC) inhibitor discovered by Parion, a privately-held, development-stage pharmaceutical company dedicated to treating serious diseases resulting from the failure of the body's mucosal defenses. The agreement grants Gilead worldwide commercialization rights to P-680 for the treatment of pulmonary diseases, including cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD) and non-CF bronchiectasis. In addition, the companies will collaborate on a research program to identify other...
Source: Clinical Trials Week (2007-08-27)
|
